Stockscreener 앱 받기
2.09
18.99%
-0.49
시간 외 거래:
2.27
0.18
+8.61%
Cyclerion Therapeutics Inc 주식(CYCN)의 최신 뉴스
Cyclerion Therapeutics Inc (CYCN) Quarterly 10-Q Report - Quartz
Cyclerion Therapeutics stock hits 52-week low at $1.75 By Investing.com - Investing.com South Africa
Cyclerion Therapeutics stock hits 52-week low at $1.75 - Investing.com India
Where Are They Now? Ironwood Pharmaceuticals - Life Science Leader Magazine
Vascular Dementia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Charsire Biotech Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP - Barchart
cyclerion therapeutics, inc. Earnings dates - RTTNews
Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 8.1% - Defense World
Analyzing Cyclerion Therapeutics (NASDAQ:CYCN) and Seelos Therapeutics (NASDAQ:SEEL) - Defense World
Cyclerion appoints Regina Graul as CEO and President - Investing.com
Cyclerion Therapeutics Promotes Regina Graul, Ph.D., to Chief Executive Officer - citybiz
Regina Graul, Ph.D., Promoted to Chief Executive Officer - StreetInsider.com
Short Interest in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Expands By 10.9% - Defense World
Cyclerion Therapeutics - BioSpace
Head-To-Head Analysis: Genelux (NASDAQ:GNLX) and Cyclerion Therapeutics (NASDAQ:CYCN) - Defense World
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday - Quantisnow
12 Health Care Stocks Moving In Thursday's Intraday SessionAethlon Medical (NASDAQ:AEMD), Biomea Fusion ... - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday SessionAutonomix Medical (NASDAQ:AMIX), Avinger ... - Benzinga
Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 10.2% - Defense World
Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates - Yahoo Movies UK
How Much Did Cyclerion Therapeutics'(NASDAQ:CYCN) Shareholders Earn From Share Price Movements Over The ... - Yahoo New Zealand News
12 Best Biotech Penny Stocks to Invest In - Insider Monkey
Cyclerion Appoints Regina Graul, Ph.D., as President - citybiz
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - GlobeNewswire
Cyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With Losses - Yahoo Finance
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer - Marketscreener.com
Cyclerion in Talks on Buyout Proposal for Drug Assets; CEO Offers to Make Equity Investment - Marketscreener.com
Rapport Therapeutics Appoints Chief Operating Officer and Scientific Advisory Board Member - Business Wire
Tisento Therapeutics Raises $81M in Series A Funding - FinSMEs
Bio Startup Tisento Launches With $81M and a Brain-Penetrating Drug in the Clinic - MedCity News
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Cyclerion Announces Reverse Stock Split - Yahoo Finance
A struggling biotech wraps its main assets into a new drug company - BioPharma Dive
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 - GlobeNewswire
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement - GlobeNewswire
Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as Chief Scientific Officer - Business Wire
BioMarin, Cyclerion Slash Workforce in the Name of Strategic Focus - BioSpace
Nasdaq Edges Higher; AngioDynamics Shares Plummet | Markets Insider - Markets Insider
Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth? - Yahoo Finance
Form 8-K Cyclerion Therapeutics, For: Jun 10 - StreetInsider.com
Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results - Yahoo Finance
David Greenspan's Slate Path Capital is Buying Coinbase, Stitch Fix, and More - Insider Monkey
Meme Penny Stocks Are Here to Stay; 3 For Your Summer Watchlist - Penny Stocks
Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat - GlobeNewswire
Hedge Fund and Insider Trading News: Dan Kamensky, Tiger Global Management, Bridgewater Associates, Standard General, Archegos Capital Management, Cyclerion Therapeutics Inc (CYCN), Sayona Mining Ltd (DMNXF), and More - Insider Monkey
Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress - GlobeNewswire
Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors - citybiz
Cyclerion Therapeutics Announces Departure of Chief Medical Officer - GlobeNewswire
IXICO selected by Cyclerion for new Alzheimer's disease study - PR Newswire
Cyclerion Therapeutics (NASDAQ:CYCN) Stock Quotes, Forecast and News Summary - Benzinga
Cyclerion Therapeutics Inc (NASDAQ:CYCN) Publishes The Results Of Its IW-6463 Phase 1 Transitional Pharmacology Study - BP Journal
Cyclerion Suspends Development of Olinciguat for Sickle Cell Disease - Sickle Cell Disease News
Cyclerion Presents Bad News in Sickle Cell Study, Good News in CNS Trial - BioSpace
Best Stocks to Buy • Benzinga - Benzinga
Cyclerion Therapeutics Completes $24 Million Private Placement - GlobeNewswire
Cyclerion Therapeutics, Inc. (CYCN) Is Burning These Hedge Funds - Insider Monkey
Mid-Morning Market Update: Markets Mostly Flat; General Electric Earnings Top ExpectationsBig 5 Sporti - Benzinga
InSphero human liver disease platform selected to test Cyclerion's sGC stimulator technology as potential therapeutic approach for NASH and fibrosis - BioSpace
Best Stocks Under $5 Right Now • BenzingaInvesting - Benzinga
Ironwood Pharmaceuticals Relocating HQ from Cambridge to Downtown Boston - Globe St.
Cambridge’s Ironwood Pharma moving HQ to downtown Boston - The Business Journals
The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana - Yahoo Finance
BioMed Realty signs Cyclerion Therapeutics to 114,454 s/f lease at 301 Binney St. in East Cambridge, Mass. - New England Real Estate Journal Online
CYCN Stock Price and Chart — NASDAQ:CYCN - TradingView
As Ironwood spinout Cyclerion launches on the Nasdaq, CEO Hecht sees 'a fresh start' - The Business Journals
Ironwood Pharma Spins off Cyclerion Therapeutics With 5 Orphan Disease Compounds - BioSpace
Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering - Business Wire
Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials - Business Wire
Ironwood co-founder, CEO will step down to head new spinout - The Business Journals
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
InvestorsHubNYSE, NASDAQ, AMEX, OTCBB, Pink Sheet Stock Message Boards, Stock Charts, Stock Quotes, Level ... - InvestorsHub
3.66%
1.11%
자본화:
|
볼륨(24시간):